Protective effect of ketotifen and disodium cromoglycate against bronchoconstriction induced by aspirin, benzoic acid or tartrazine in intolerant asthmatics.
Oral challenge tests with acetylsalicylic acid, tartrazine or benzoic acid were performed in 7 intolerant asthmatic patients after a 3-day treatment with either orally taken ketotifen (1 mg twice daily) or inhaled disodium cromoglycate (20 mg four times daily) at random. Protection was noted with ketotifen in 5, with DSCG in 3 patients. On the evaluation of the mean percentage of the maximum decline in the forced expiratory volume in 1 sec (FEV1) only ketotifen afforded significant protection statistically (p less than 0.05). All the intolerant asthmatics studies showed, as an immunological abnormity, a slight, but significant decrease of the C1-inhibitor levels. Moreover, in three out of these the alpha 1-antitrypsin serum values were under the lower normal range.
D000328:Adult; D000368:Aged; D001241:Aspirin / Q000009:adverse effects; D001249:Asthma / Q000097:blood / Q000517:prevention & control*; D001565:Benzoates / Q000009:adverse effects; D001986:Bronchial Spasm / Q000517:prevention & control*; D003174:Complement C1 Inactivator Proteins / Q000097:blood; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D013645:Tartrazine / Q000009:adverse effects; D013876:Thiophenes / Q000627:therapeutic use*; D000515:alpha 1-Antitrypsin / Q000097:blood
D001565:Benzoates; D003174:Complement C1 Inactivator Proteins; D010880:Piperidines; D013876:Thiophenes; D000515:alpha 1-Antitrypsin; D013645:Tartrazine; D004205:Cromolyn Sodium; D001241:Aspirin